LYRA
NASDAQ · Pharmaceuticals
Lyra Therapeutics Inc
$0.19
+0.00 (+0.00%)
Financial Highlights (FY 2026)
Revenue
454.7K
Net Income
-33,040,711
Gross Margin
—
Profit Margin
-7,266.1%
Rev Growth
-33.6%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 60.3% | 60.3% |
| Operating Margin | -7,794.5% | -7,015.0% | 33.2% | 29.0% |
| Profit Margin | -7,266.1% | -6,902.8% | 24.8% | 19.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 454.7K | 684.9K | 681.7K | 558.5K |
| Gross Profit | — | — | 411.1K | 336.8K |
| Operating Income | -35,443,403 | -48,047,993 | 226.6K | 162.2K |
| Net Income | -33,040,711 | -44,790,841 | 169.3K | 107.5K |
| Gross Margin | — | — | 60.3% | 60.3% |
| Operating Margin | -7,794.5% | -7,015.0% | 33.2% | 29.0% |
| Profit Margin | -7,266.1% | -6,902.8% | 24.8% | 19.3% |
| Rev Growth | -33.6% | -33.6% | +3.7% | -9.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 1.04M | 1.08M |
| Total Equity | — | — | 1.55M | 1.59M |
| D/E Ratio | — | — | 0.67 | 0.68 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -34,919,071 | -49,967,039 | 337.6K | 271.6K |
| Free Cash Flow | — | — | 110.0K | 71.2K |